Advances in the management of basal cell carcinoma

F1000Prime Reports

Volumn 7, Issue , 2015, Pages

  Lewin, Jesse M ^a   Carucci, John A ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMIQUIMOD;

BASAL CELL CARCINOMA; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CRYOSURGERY; CURETTAGE; ELECTRODESICCATION; ELECTROSURGERY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUPERFICIAL X-RAY THERAPY; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW (TOPIC); TUMOR SUPPRESSOR GENE; ULTRAVIOLET B RADIATION;

EID: 84929452468     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P7-53     Document Type: Review

References (71)

1. Mohan SV, Chang, Anne Lynn S: Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations. Curr Dermatol Rep 2014, 3:40-5.
2. Baxter JM, Patel AN, Varma S: Facial basal cell carcinoma. BMJ 2012, 345:e5342.
3. Rigel DS, Friedman RJ, Kopf AW: Lifetime risk for development of skin cancer in the U.S. population: current estimate is now 1 in 5. J Am Acad Dermatol 1996, 35:1012-3.
4. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, Roenigk RK: Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005, 294:681-90.
5. Vries E de, Louwman M, Bastiaens M, Gruijl F de, Coebergh JW: Rapid and continuous increases in incidence rates of basal cell carcinoma in the southeast Netherlands since 1973. J Invest Dermatol 2004, 123:634-8.
6. Delfino S, Innocenzi D, Di Lorenzo G, Scalvenzi M, Montesarchio V, Feroce F, Baldi A, Persichetti P: An increase in basal cell carcinoma among the young: an epidemiological study in a middle-south Italian population. Anticancer Res 2006, 26:4979-83.
7. Wu TP, Stein JA: Nonmelanoma skin cancer in young women. J Drugs Dermatol 2013, 12:568-72.
8. Scrivener Y, Grosshans E, Cribier B: Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol 2002, 147:41-7.
9. Weinstock MA, Fisher DE: Indoor ultraviolet tanning: what the data do and do not show regarding risk of melanoma and keratinocyte malignancies. J Natl Compr Canc Netw 2010, 8:867-72; quiz 873.
10. Nan H, Kraft P, Hunter DJ, Han J: Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer 2009, 125:909-17.
11. Karimkhani C, Boyers LN, Dellavalle RP, Weinstock MA: It's time for 'keratinocyte carcinoma' to replace the term 'nonmelanoma skin cancer'. J Am Acad Dermatol 2015, 72:186-7.
12. Gailani MR, Leffell DJ, Ziegler A, Gross EG, Brash DE, Bale AE: Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma. J Natl Cancer Inst 1996, 88:349-54.
13. van Dam RM, Huang Z, Rimm EB, Weinstock MA, Spiegelman D, Colditz GA, Willett WC, Giovannucci E: Risk factors for basal cell carcinoma of the skin in men: results from the health professionals follow-up study. Am J Epidemiol 1999, 150:459-68.
14. Situm M, Buljan M, Bulat V, Lugović Mihić L, Bolanca Z, Simić D: The role of UV radiation in the development of basal cell carcinoma. Coll Antropol 2008, 32(Suppl 2):167-70.
15. Helveston EM, Wilson DL: A suture-reinforced scleral sling. Technique for suspension of the ptotic upper lid. Arch Ophthalmol 1975, 93:643-5.
16. Swanson NA: Otolaryngology Head & Neck Surgery. 3rd ed. St. Louis: Mosby; 1998.
17. Salasche SJ, Amonette RA: Morpheaform basal-cell epitheliomas. A study of subclinical extensions in a series of 51 cases. J Dermatol Surg Oncol 1981, 7:387-94.
18. Niazi ZB, Lamberty BG: Perineural infiltration in basal cell carcinomas. Br J Plast Surg 1993, 46:156-7.
19. Ratner D, Lowe L, Johnson TM, Fader DJ: Perineural spread of basal cell carcinomas treated with Mohs micrographic surgery. Cancer 2000, 88:1605-13.
20. Dunn M, Morgan MB, Beer TW: Perineural invasion: identification, significance, and a standardized definition. Dermatol Surg 2009, 35:214-21.
21. Ozgediz D, Smith EB, Zheng J, Otero J, Tabatabai ZL, Corvera CU: Basal cell carcinoma does metastasize. Dermatol Online J 2008, 14:5.
22. Domarus H von, Stevens PJ: Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 1984, 10:1043-60.
23. Danial C, Lingala B, Balise R, Oro AE, Reddy S, Colevas A, Chang ALS: Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. Br J Dermatol 2013, 169:673-6.
24. Chiller K, Passaro D, McCalmont T, Vin-Christian K: Efficacy of curettage before excision in clearing surgical margins of nonmelanoma skin cancer. Arch Dermatol 2000, 136:1327-32.
25. Wolf DJ, Zitelli JA: Surgical margins for basal cell carcinoma. Arch Dermatol 1987, 123:340-4.
26. Kimyai-Asadi A, Alam M, Goldberg LH, Peterson SR, Silapunt S, Jih MH: Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas. J Am Acad Dermatol 2005, 53:464-8.
27. Farhi D, Dupin N, Palangié A, Carlotti A, Avril M: Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases. Dermatol Surg 2007, 33:1207-14.
28. Bieley HC, Kirsner RS, Reyes BA, Garland LD: The use of Mohs micrographic surgery for determination of residual tumor in incompletely excised basal cell carcinoma. J Am Acad Dermatol 1992, 26:754-6.
29. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol 2005, 53:452-7.
30. Mosterd K, Krekels, Gertruud AM, Nieman FH, Ostertag JU, Essers, Brigitte AB, Dirksen CD, Steijlen PM, Vermeulen A, Neumann H, Kelleners-Smeets, Nicole WJ: Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol 2008, 9:1149-56.
31. Mohs FE: Chemosurgery: a microscopically uncontrolled method of cancer excision. Arch Surg 1941, 42:279-95.
32. Mohs FE: Chemosurgery, microscopically controlled surgery for skin cancer. Springfield: Thomas; 1978.
33. Lawrence CM: Mohs' micrographic surgery for basal cell carcinoma. Clin Exp Dermatol 1999, 24:130-3.
34. Bernstein PE: Mohs' 98: single-procedure Mohs surgery with immediate reconstruction. Otolaryngol Head Neck Surg 1999, 120:184-9.
35. Shriner DL, McCoy DK, Goldberg DJ, Wagner RF: Mohs micrographic surgery. J Am Acad Dermatol 1998, 39:79-97.
36. Takamori S, Kong K, Varma S, Leach I, Williams HC, Notingher I: Optimization of multimodal spectral imaging for assessment of resection margins during Mohs micrographic surgery for basal cell carcinoma. Biomed Opt Express 2015, 6:98-111.
37. Rowe DE, Carroll RJ, Day CL: Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989, 15:315-28.
38. Rowe DE, Carroll RJ, Day CL: Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989, 15:424-31.
39. Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, Vidimos AT, Zalla MJ, Brewer JD, Smith Begolka W, Berger TG, Bigby M, Bolognia JL, Brodland DG, Collins S, Cronin TA, Dahl MV, Grant-Kels JM, Hanke CW, Hruza GJ, James WD, Lober CW, McBurney EI, Norton SA, Roenigk RK, Wheeland RG, Wisco OJ: AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol 2012, 67:531-50.
40. American Academy of Dermatology: Mohs Surgery Appropriate Use Criteria (AUC) app. [https://www.aad.org/education/appropriate-use-criteria/mohs-auc-app].
41. Rodriguez-Vigil T, Vázquez-López F, Perez-Oliva N: Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol 2007, 56:91-5.
42. Spiller WF, Spiller RF: Treatment of basal cell epithelioma by curettage and electrodesiccation. J Am Acad Dermatol 1984, 11:808-14.
43. Goldman G: The current status of curettage and electrodesiccation. Dermatol Clin 2002, 20:569-78, ix.
44. Ceilley RI, Del Rosso, James Q: Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol 2006, 45:489-98.
45. Thissen MR, Neumann MH, Schouten LJ: A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999, 135:1177-83.
46. Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, Owens M: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002, 47:390-8.
47. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004, 50:722-33.
48. Roozeboom MH, Nelemans PJ, Mosterd K, Steijlen PM, Arits, AHMM, Kelleners-Smeets, NWJ: Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial. Br J Dermatol 2014.
49. Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller, Paul SJ, Williams HC: Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 2014, 15:96-105.
50. Murphy ME, Brodland DG, Zitelli JA: Definitive surgical treatment of 24 skin cancers not cured by prior imiquimod therapy: a case series. Dermatol Surg 2008, 34:1258-63.
51. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA: a cancer journal for clinicians. 2005, 55:10-30.
52. Arits, Aimée HMM, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij, Michette JM, van Pelt, Han PA, Quaedvlieg, Patricia JF, Krekels, Gertruud AM, van Neer, Pierre AFA, Rijzewijk JJ, van Geest, Adrienne J, Steijlen PM, Nelemans PJ, Kelleners-Smeets, Nicole WJ: Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013, 14:647-54.
53. Gross K, Kircik L, Kricorian G: 5% 5-Fluorouracil cream for the treatment of small superficial Basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg 2007, 33:433-9; discussion 440.
54. Xiong MY, Korgavkar K, Digiovanna JJ, Weinstock MA: Fluorouracil and other predictors of morpheaform basal cell carcinoma among high-risk patients: the Veterans Affairs Topical Tretinoin Chemoprevention Trial. JAMA Dermat 2014, 150:332-4.
55. Szpringer E, Lutnicki K, Marciniak A: Photodynamic therapy - mechanism and employment. Ann Univ Mariae Curie Sklodowska Med 2004, 59:498-502.
56. Szeimies RM, Ibbotson S, Murrell DF, Rubel D, Frambach Y, Berker D de, Dummer R, Kerrouche N, Villemagne H: A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008, 22:1302-11.
57. Roozeboom MH, Aardoom MA, Nelemans PJ, Thissen Monique RTM, Kelleners-Smeets NW, Kuijpers DI, Mosterd K: Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. J Am Acad Dermatol 2013, 69:280-7.
58. Bath-Hextall FJ, Perkins W, Bong J, Williams HC: Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007: CD003412.
59. Griep C, Davelaar J, Scholten AN, Chin A, Leer JW: Electron beam therapy is not inferior to superficial x-ray therapy in the treatment of skin carcinoma. Int J Radiat Oncol Biol Phys 1995, 32:1347-50.
60. Cognetta AB, Howard BM, Heaton HP, Stoddard ER, Hong HG, Green WH: Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J Am Acad Dermatol 2012, 67:1235-41.
61. Avril MF, Auperin A, Margulis A, Gerbaulet A, Duvillard P, Benhamou E, Guillaume JC, Chalon R, Petit JY, Sancho-Garnier H, Prade M, Bouzy J, Chassagne D: Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 1997, 76:100-6.
62. Wollina U, Tchernev G: Advanced basal cell carcinoma. Wien Med Wochenschr 2013, 163:347-53.
63. Epstein EH: Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008, 8:743-54.
64. Aszterbaum M, Rothman A, Johnson RL, Fisher M, Xie J, Bonifas JM, Zhang X, Scott MP, Epstein EH: Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol 1998, 110:885-8.
65. Atwood SX, Chang, Anne Lynn S, Oro AE: Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol 2012, 199:193-7.
66. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang, Anne Lynn S, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A: Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012, 366:2171-9.
67. Jimeno A, Weiss GJ, Miller WH, Gettinger S, Eigl Bernard JC, Chang, Anne Lynne S, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM: Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res 2013, 19:2766-74.
68. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH: Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012, 366:2180-8.
69. Loftus P: New Drugs Treat Advanced Stages of a Common Skin Cancer. The Wall Street Journal; 2014. [http://www.wsj.com/articles/new-drugs-treat-advanced-stages-of-a-common-skin-cancer-1416869882?KEYWORDS=basal+cell+carcinoma.].
70. Madan V, Lear JT, Szeimies R: Non-melanoma skin cancer. Lancet 2010, 375:673-85.
71. Linos E, Parvataneni R, Stuart SE, Boscardin WJ, Landefeld CS, Chren M: Treatment of nonfatal conditions at the end of life: nonmelanoma skin cancer. JAMA Intern Med 2013, 173:1006-12.